Nicotinamide adenine dinucleotide (NAD+) is an essential pyridine nucleotide coenzyme central to cellular respiration, bioenergetics, and enzymatic signaling. In preclinical research, intranasal administration pathways of NAD+ are studied to evaluate direct central nervous system bypass of first-pass hepatic metabolism. PX1 Research supplies ultra-pure, research-grade NAD+ specifically manufactured for in vitro assays and animal research models.
Nicotinamide adenine dinucleotide (NAD+) is an essential pyridine nucleotide coenzyme central to cellular respiration, bioenergetics, and enzymatic signaling. In preclinical research, intranasal administration pathways of NAD+ are studied to evaluate direct central nervous system bypass of first-pass hepatic metabolism. PX1 Research supplies ultra-pure, research-grade NAD+ specifically manufactured for in vitro assays and animal research models.
Nasal NAD+ refers to the formulation and study of nicotinamide adenine dinucleotide administered via the nasal mucosa in animal and cellular research models. This delivery pathway is investigated in laboratory settings to evaluate its ability to bypass the blood-brain barrier via olfactory and trigeminal neuronal networks, enabling researchers to measure direct central nervous system coenzyme bioenergetics without reliance on peripheral oral or systemic metabolism.
In physiological biochemistry, NAD+ exists in two interconvertible forms: oxidized NAD+ and reduced NADH. The ratio of NAD+ to NADH serves as a key metabolic sensor that regulates intracellular redox states and drives adenosine triphosphate (ATP) synthesis through mitochondrial oxidative phosphorylation. When researchers examine research-grade NAD+ in laboratory settings, the primary objective is often to observe how localized or central elevations in pyridine nucleotide pools influence downstream signaling enzymes, such as sirtuins (SIRT1–SIRT7) and poly(ADP-ribose) polymerases (PARPs).
Because oral administration of intact NAD+ typically results in extensive enzymatic degradation within the gastrointestinal tract and rapid hepatic conversion into secondary metabolites, preclinical investigators utilize specialized administration routes—including intranasal instillation in rodent models—to assess localized tissue absorption. Research protocols documented in our PX1 research library hub highlight how intranasal pathways facilitate transport across the olfactory epithelium, providing an ideal model for exploring central neuroenergetics and neuroprotective pathways.
At the cellular level, NAD+ functions as a essential co-substrate for enzymes that govern metabolic homeostasis, genomic stability, and epigenetic regulation. Preclinical studies indicate that intracellular depletion of NAD+ correlates with diminished mitochondrial respiration, increased oxidative stress, and impaired DNA repair mechanisms. By supplying exogenous NAD+ to cell culture models or animal tissue lysates, researchers can quantitatively measure alterations in cellular energy output and catalytic enzyme activity.
Sirtuins, particularly SIRT1 and SIRT3, are NAD+-dependent deacetylases that regulate mitochondrial biogenesis, antioxidant gene expression, and fatty acid oxidation. In vitro assays demonstrate that elevating the available NAD+ substrate concentration directly enhances sirtuin catalytic velocity. Concurrently, PARP enzymes rely on NAD+ to synthesize ADP-ribose polymers during single-strand and double-strand DNA repair processes. Understanding the competitive consumption of NAD+ between sirtuins and PARPs represents a critical focus within molecular gerontology and oncology research.
Furthermore, CD38 and CD157 represent major NAD+-consuming ectoenzymes that hydrolyze NAD+ into nicotinamide and cyclic ADP-ribose (cADPR). In preclinical rodent models of metabolic stress, inhibition of CD38 expression alongside exogenous NAD+ supplementation has been shown to restore tissue NAD+ homeostasis. Investigators examining these mechanisms routinely utilize standardized analytical assays to map kinetic alterations in cADPR signaling and downstream intracellular calcium mobilization.
The anatomical rationale for studying nasal NAD+ in rodent models centers on the unique architecture of the nasal cavity. The olfactory mucosa provides a direct anatomical interface between the external environment and the rostral brain structures, specifically the olfactory bulb and cerebral spinal fluid (CSF) compartments. Preclinical investigation shows that small molecules and intact nucleotides can traverse the perineural spaces surrounding olfactory nerve bundles, bypassing the tight junctions of the blood-brain barrier (BBB).
In murine models, intranasal instillation of radiolabeled or fluorescently tagged NAD+ solutions allows researchers to quantify tissue distribution across discrete central brain regions, including the hippocampus, cortex, and cerebellum. Comparative tissue homogenate studies demonstrate that intranasal application yields significantly higher central brain NAD+ concentrations relative to equivalent intraperitoneal or intravenous doses, while minimizing systemic clearance rates.
Researchers evaluating intranasal protocols must account for physiological variables unique to laboratory animal models, such as mucosal clearance rates, enzymatic activity of localized mucosal peptidases and nucleosidases, and solution osmolarity. To maintain consistent experimental conditions, standardized vehicle buffers with controlled pH and ionic strength are implemented across all experimental cohorts.
Preclinical studies exploring central NAD+ repletion have documented notable outcomes in models of neurodegenerative stress, cerebral ischemia, and metabolic dysfunction. In rodent models of transient focal ischemia, intranasal administration of NAD+ performed post-injury significantly reduced cerebral infarction volume and attenuated neuronal apoptosis within ischemic penumbra tissues.
In vitro data indicate that incubating primary cortical neurons or microglial cultures with exogenous NAD+ mitigates excitotoxic injury induced by excessive glutamate exposure. Furthermore, in animal models evaluating neuroinflammatory cascades, elevated central NAD+ levels correlated with decreased microglial activation markers and down-regulated expression of pro-inflammatory cytokines such as TNF-alpha and IL-1 beta.
Metabolic research models focused on age-related cognitive decline also highlight the role of restored mitochondrial respiration. Mouse models receiving targeted intranasal NAD+ display improved performance in spatial memory tasks and novel object recognition assays, accompanied by increased biochemical markers of hippocampal synaptic plasticity, such as brain-derived neurotrophic factor (BDNF) and phosphorylated CREB.
When designing metabolic and longevity studies, researchers frequently evaluate NAD+ alongside its biosynthetic precursors and complementary mitochondrial research compounds. Understanding the distinct biochemical entry points of these molecules is vital for selecting the correct experimental controls.
Nicotinamide mononucleotide (NMN) and nicotinamide riboside (NR) serve as immediate enzymatic precursors within the salvage pathway. While NMN and NR require transport proteins (such as Slc12a8 for NMN) or enzymatic conversion via nicotinamide riboside kinases (NRKs) to yield intracellular NAD+, direct NAD+ instillation provides the intact dinucleotide molecule. In contrast, targeted mitochondrial peptides act through distinct structural mechanisms: MOTS-c is a mitochondria-derived peptide that regulates nuclear gene expression during metabolic stress, while SS-31 targets cardiolipin in the inner mitochondrial membrane to optimize electron transport chain efficiency.
For comprehensive comparative protocols, laboratories often utilize baseline controls across multiple compound classes. Exploring our catalog of all research peptides provides institutional buyers with access to standardized, high-purity compounds synthesized to ensure rigorous cross-comparison in metabolic and bioenergetic research.
Lyophilized NAD+ is a hygroscopic, white to off-white crystalline powder that requires meticulous handling to prevent hydrolytic degradation. To prepare NAD+ solutions for in vitro assays or intranasal animal studies, researchers must reconstitute the compound using sterile, cold, non-pyrogenic buffers such as phosphate-buffered saline (PBS) or sterile water for injection (pH 6.0–7.0).
NAD+ is chemically less stable in solution than its oxidized precursors and is highly susceptible to temperature-dependent hydrolysis into nicotinamide and ADP-ribose. Reconstitution should be performed immediately prior to experimental administration, maintaining the solution on ice (2°C–4°C) throughout the handling process. Avoid exposure to strongly alkaline or strongly acidic conditions, as extreme pH shifts accelerate nucleosidic cleavage.
When preparing stock solutions for quantitative enzymatic assays, researchers should confirm final concentration via UV spectrophotometry using the characteristic extinction coefficient of NAD+ at 260 nm (18,000 M⁻¹cm⁻¹). Aliquoting reconstituted stock into single-use microcentrifuge tubes minimizes freeze-thaw degradation cycles during longitudinal laboratory trials.
To preserve structural integrity and prevent moisture absorption, lyophilized NAD+ research material must be stored at -20°C in a desiccated environment. Under these conditions, unopened vials maintain validated stability profiles for extended research durations.
Upon receipt of shipment from PX1 Research, vials should be inspected and transferred immediately to dedicated freezer storage. Prior to opening the vial for weighing or reconstitution, allow the container to equilibrate to room temperature within a laminar flow hood or desiccator cabinet. Opening frozen vials without temperature equilibration causes ambient atmospheric moisture to condense onto the powder, initiating premature hydrolysis.
All procedures involving research-grade NAD+ should be conducted by qualified laboratory personnel utilizing appropriate personal protective equipment (PPE), including nitrile gloves, eye protection, and laboratory coats, adhering strictly to institutional biosafety guidelines for chemical handling.
Precise experimental replication demands research compounds that meet absolute purity and analytical verification standards. Low-purity material or unresolved synthetic byproducts introduce unwanted variables into delicate enzymatic and cellular assays.
Every lot of NAD+ supplied by PX1 Research undergoes rigorous testing using Reverse-Phase High-Performance Liquid Chromatography (RP-HPLC) to verify chemical purity exceeding 98%. Analytical HPLC chromatograms confirm the absence of degradation products such as free nicotinamide, adenosine monophosphate (AMP), or breakdown fragments that could interfere with enzymatic reaction kinetics.
Electrospray Ionization Mass Spectrometry (ESI-MS) is performed concurrently to confirm exact molecular mass and identity (molecular formula: C21H27N7O14P2; exact mass: 663.11 g/mol). Additionally, because intranasal and central nervous system preclinical studies are exceptionally sensitive to bacterial contaminants, our lot verification protocols include Limulus Amebocyte Lysate (LAL) testing to ensure endotoxin levels remain strictly below <0.01 EU/mg.
PX1 Research operates as a premier USA-based supplier of high-purity research compounds, catering exclusively to academic institutions, biotechnology companies, and independent research laboratories. All compounds are manufactured in compliance with strict Good Manufacturing Practice (GMP) standards within ISO 17025 accredited laboratory facilities.
We enforce full lot traceability across our entire catalog. Each order is accompanied by a downloadable, lot-specific Certificate of Analysis (COA) detailing raw HPLC integration data, mass spectra, moisture content analysis, and certified endotoxin thresholds. Orders placed Monday through Friday ship same-day from our primary distribution hubs in California and Arizona.
Institutional researchers requiring custom bulk quantities, specialized research buffers, or dedicated account management for ongoing preclinical trials are encouraged to explore our dedicated lab wholesale programs or consult our scientific support staff for technical documentation.
What is nasal NAD+ in a laboratory setting?
Nasal NAD+ refers to research-grade nicotinamide adenine dinucleotide prepared for intranasal instillation in animal models or tissue models. It is studied to evaluate direct central nervous system bioenergetics and blood-brain barrier bypass mechanisms without systemic metabolic clearance.
How does intranasal NAD+ bypass the blood-brain barrier in preclinical studies?
In animal models, intranasally instilled compounds traverse the perineural and perivascular spaces of the olfactory and trigeminal nerve pathways in the nasal cavity, transporting directly into the cerebrospinal fluid and olfactory bulb structures.
What analytical tests verify the purity of PX1 Research NAD+?
PX1 Research verifies every lot of NAD+ using Reverse-Phase High-Performance Liquid Chromatography (RP-HPLC) for purity (>98%), Electrospray Ionization Mass Spectrometry (ESI-MS) for molecular weight confirmation, and Limulus Amebocyte Lysate (LAL) assays for endotoxin quantification.
What is the recommended buffer for reconstituting research-grade NAD+?
NAD+ should be reconstituted in cold, sterile, non-pyrogenic buffers such as phosphate-buffered saline (PBS) or sterile water for injection at neutral pH (6.0–7.0). Solutions must be kept on ice during handling to limit hydrolytic breakdown.
How should lyophilized NAD+ be stored upon arrival?
Lyophilized NAD+ must be stored at -20°C in a dry, desiccated freezer container. Vials should be allowed to reach room temperature before opening to avoid atmospheric moisture condensation on the powder.
How does NAD+ differ from mitochondrial peptides like MOTS-c or SS-31?
NAD+ is a direct pyridine nucleotide coenzyme essential for sirtuin and PARP enzymatic activity. In contrast, MOTS-c is a mitochondria-derived signaling peptide regulating nuclear gene expression, while SS-31 is a peptide that specifically binds cardiolipin to optimize mitochondrial membrane energetics.
Where does PX1 Research manufacture and ship its research compounds?
All PX1 Research compounds are manufactured in USA-based ISO 17025 accredited facilities. Orders ship same-day (Monday through Friday) from our fulfillment centers located in California and Arizona.
Is NAD+ provided by PX1 Research suitable for human clinical use?
No. All products supplied by PX1 Research are strictly for laboratory research, in vitro assays, and preclinical animal investigation. They are not intended for human consumption, clinical diagnostic procedures, or therapeutic administration.
All products are sold strictly for laboratory and research use only. Not for human or veterinary use, diagnosis, treatment or consumption. Statements have not been evaluated by the FDA.